MXPA04000028A - Formulacion farmaceutica para la administracion intramuscular de fulvestrant. - Google Patents

Formulacion farmaceutica para la administracion intramuscular de fulvestrant.

Info

Publication number
MXPA04000028A
MXPA04000028A MXPA04000028A MXPA04000028A MXPA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
fulvestrant
intramuscular administration
administration
ricinoleate vehicle
Prior art date
Application number
MXPA04000028A
Other languages
English (en)
Spanish (es)
Inventor
Kay Cahill Julie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04000028A publication Critical patent/MXPA04000028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MXPA04000028A 2001-07-07 2004-01-07 Formulacion farmaceutica para la administracion intramuscular de fulvestrant. MXPA04000028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30

Publications (1)

Publication Number Publication Date
MXPA04000028A true MXPA04000028A (es) 2004-05-21

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000028A MXPA04000028A (es) 2001-07-07 2004-01-07 Formulacion farmaceutica para la administracion intramuscular de fulvestrant.

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US8586092B2 (en) 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
US20220370359A1 (en) * 2019-12-11 2022-11-24 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
IS7097A (is) 2004-01-05
CA2453111A1 (en) 2003-01-23
JP2004534093A (ja) 2004-11-11
WO2003006064A1 (en) 2003-01-23
CO5560585A2 (es) 2005-09-30
NO20040047L (no) 2004-02-23
RU2004102393A (ru) 2005-03-27
BR0210898A (pt) 2004-06-22
IL159576A0 (en) 2004-06-01
EP1406662A1 (en) 2004-04-14
HUP0400115A2 (hu) 2004-06-28
AR037138A1 (es) 2004-10-27
CN1553815A (zh) 2004-12-08
HUP0400115A3 (en) 2005-11-28
PL367624A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
ES2186517A1 (es) Formulacion farmaceutica que contiene fulvestrant.
MXPA04000028A (es) Formulacion farmaceutica para la administracion intramuscular de fulvestrant.
WO2002100344A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
WO2006052921A3 (en) Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2003099338A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA03000442A (es) Una formulacion medicinal en aerosol.
PT1123120E (pt) Formulacao medicinal em aerossol
EP1938821A3 (en) Methods of administering epothilone analogs for the treatment of cancer
ATE225174T1 (de) Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
WO2002042414A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
GT199800196A (es) Combinaciones de estatina-eter carboxialquilico.
BR0312004A (pt) Composições de aerossol transdérmicas
AR018888A1 (es) Un derivado de testosterona, uso del mismo, una formulacion farmaceutica que comprende a dicho derivado y un kit para la anticoncepcion masculina
HK1052946A1 (en) Dry compositions containing hydrophobic amino acid
DE60017720D1 (de) Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
ES2141049A1 (es) Formulaciones farmaceuticas en aerosol que contienen trigliceridos de cadena media como surfactantes.